19.07.2012 - On the Iberian Peninsula opposition against the drastic budget cuts is forming. Big pharma is not immune from the cuts.
The Spanish R&D budget for 2012 has been slashed to 75% of last year’s value. Although the Spanish secretary of state for research, Carmen Vela, defends the plan saying that the „system is oversized and Spanish science could do more with less“, the affected sector howls in disagreement. „Excellence costs money and we will not reach it by shrinking investment“, says Carlos Andradas. Andradas is the president of the Confederation of Spanish Scientific Societies (COSCE). Together with other reputable science organisations in the country, COSCE demands the European Parliament to take action. In a letter sent to European Parliamentarians at the beginning of June, the Spanish scientists draw a comparison to Europe’s power in the economy: „The European Union is issuing recommendations on economic matters that governments take very seriously. We would like to hear recommendations on R&D spending as well“, says Andrades. So far no reactions from Strasbourg have been noted.
Portuguese healthcare is contending with different weapons. Last week, doctors and nurses went on a two-day workout with only emergency services left unaffected. The government’s actions to shrink its budget deficit threaten the quality of the healthcare system, say the unions. Reformers seem to get caught in crossfire as international pharma and chemistry businesses also raise the pressure. Merck KGAA from Darmstadt (Germany) warned the Portuguese government on 9 July that planned research projects worth €2m could be cancelled if the hospitals do not stick to the settlements regarding the liquidation of debts. According to information from the German newspaper FTD, the Portuguese hospitals alone owe the pharma industry about €1.5bn. Companies have to wait on average 550 days until their bills are cleared.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.
09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.
06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.